BR112013012811B8 - Peptídeo derivado de lactoferrina humana, e processo para preparação de uma composição farmacêutica para liberação de uma substância ativa biológica em um organismo mamífero - Google Patents

Peptídeo derivado de lactoferrina humana, e processo para preparação de uma composição farmacêutica para liberação de uma substância ativa biológica em um organismo mamífero

Info

Publication number
BR112013012811B8
BR112013012811B8 BR112013012811A BR112013012811A BR112013012811B8 BR 112013012811 B8 BR112013012811 B8 BR 112013012811B8 BR 112013012811 A BR112013012811 A BR 112013012811A BR 112013012811 A BR112013012811 A BR 112013012811A BR 112013012811 B8 BR112013012811 B8 BR 112013012811B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
active substance
biological active
human lactoferrin
mammalian organism
Prior art date
Application number
BR112013012811A
Other languages
English (en)
Other versions
BR112013012811A2 (pt
BR112013012811B1 (pt
Inventor
Hartwig Benedikt
Tome Alcalde Juan
Windhab Norbert
Del Pilar Ansuategui Panzano María
Javier Vara Carrera Matías
Original Assignee
Evonik Roehm Gmbh
Roehm Gmbh
Evonik Degussa Gmbh
Evonik Operations Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh, Roehm Gmbh, Evonik Degussa Gmbh, Evonik Operations Gmbh filed Critical Evonik Roehm Gmbh
Publication of BR112013012811A2 publication Critical patent/BR112013012811A2/pt
Publication of BR112013012811B1 publication Critical patent/BR112013012811B1/pt
Publication of BR112013012811B8 publication Critical patent/BR112013012811B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

PEPTÍDEO DERIVADO DE LACTOFERRINA HUMANA, COMPOSIÇÃO FARMACÊUTICA E SEU PROCESSO DE PREPARAÇÃO. A invenção refere-se a um peptídeo derivado de lactoferrina humana para uso como um agente de mascaramento de antígeno na produção de uma composição farmacêutica para liberação de uma substância ativa biológica em um organismo mamífero, onde a substância ativa biológica é capaz de induzir uma indesejada resposta imune pelo organismo mamífero, onde a composição farmacêutica compreende um agregado supramolecular da substância ativa biológica e o peptídeo derivado de lactoferrina humana, com o efeito de que após liberação de composição farmacêutica para o organismo mamífero, não há nenhuma ou somente uma diminuída indução da indesejada resposta imune contra a substância ativa biológica.
BR112013012811A 2010-11-26 2010-11-26 Peptídeo derivado de lactoferrina humana, e processo para preparação de uma composição farmacêutica para liberação de uma substância ativa biológica em um organismo mamífero BR112013012811B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2010/068302 WO2012069089A1 (en) 2010-11-26 2010-11-26 Human lactoferrin derived peptide for use as an antigen masking agent

Publications (3)

Publication Number Publication Date
BR112013012811A2 BR112013012811A2 (pt) 2016-09-13
BR112013012811B1 BR112013012811B1 (pt) 2021-07-06
BR112013012811B8 true BR112013012811B8 (pt) 2022-07-05

Family

ID=43837881

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013012811A BR112013012811B8 (pt) 2010-11-26 2010-11-26 Peptídeo derivado de lactoferrina humana, e processo para preparação de uma composição farmacêutica para liberação de uma substância ativa biológica em um organismo mamífero

Country Status (17)

Country Link
US (1) US9724422B2 (pt)
EP (1) EP2643344B1 (pt)
JP (1) JP6073239B2 (pt)
KR (1) KR101765364B1 (pt)
CN (1) CN103906760B (pt)
AU (1) AU2010364538B2 (pt)
BR (1) BR112013012811B8 (pt)
CA (1) CA2818951C (pt)
ES (1) ES2627960T3 (pt)
HK (1) HK1196379A1 (pt)
HU (1) HUE033501T2 (pt)
IL (1) IL226198B (pt)
MX (1) MX348337B (pt)
PL (1) PL2643344T3 (pt)
RU (1) RU2573422C2 (pt)
SI (1) SI2643344T1 (pt)
WO (1) WO2012069089A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6588039B2 (ja) 2014-05-28 2019-10-09 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングＥｖｏｎｉｋ Ｒｏｅｈｍ ＧｍｂＨ ナノ粒子
US11225520B2 (en) 2016-02-16 2022-01-18 Dana-Farber Cancer Institute, Inc. Immunotherapy compositions and methods
DE102016008601B4 (de) 2016-07-14 2019-05-23 Giesecke+Devrient Currency Technology Gmbh Sicherheitselement mit reversibel veränderbarem Farbbereich
US11021529B2 (en) 2017-03-03 2021-06-01 Massachusetts Institute Of Technology Antimicrobial constructs and uses thereof
CN107226860B (zh) * 2017-07-06 2020-04-10 浙江辉肽生命健康科技有限公司 一种生物活性多肽skhssldcvl及其制备方法和应用
US11052053B2 (en) 2018-05-08 2021-07-06 Evonik Operations Gmbh Nanoparticle comprising a bio-resorbable polyester, a hydrophilic polymer and an acylated human lactoferrin-derived peptide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066469A (en) * 1990-03-08 2000-05-23 Ferro Dynamics, Inc. Cloning, expression, and uses of human lactoferrin
US5977337A (en) 1997-06-03 1999-11-02 Connaught Laboratories Limited Lactoferrin receptor genes of Moraxella
US6423509B1 (en) 1998-07-15 2002-07-23 Samyang Genex Corporation Pichia pastoris strain for producing lactoferrin and methods of use
JP2000045182A (ja) 1998-07-23 2000-02-15 Peptide Science:Kk 抗菌性繊維および繊維・皮革用抗菌加工剤
US20070259007A1 (en) * 1999-10-19 2007-11-08 Kruzel Marian L Lactoferrin: an adjuvant for vaccines
RU2165769C1 (ru) 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
US7785818B2 (en) * 2002-10-25 2010-08-31 Techlab, Inc. Inflammatory bowel disease and irritable bowel syndrome IBD-first chek diagnostic panel
AU2003296447A1 (en) 2002-12-10 2004-06-30 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
DE102005051366A1 (de) 2005-10-25 2007-04-26 Degussa Gmbh Drug Delivery Systeme
KR101317100B1 (ko) 2005-12-30 2013-10-15 에보니크 룀 게엠베하 세포-침투성 펩티드로서 유용한 펩티드

Also Published As

Publication number Publication date
RU2013128884A (ru) 2015-01-10
EP2643344B1 (en) 2017-03-22
US9724422B2 (en) 2017-08-08
CA2818951C (en) 2018-03-13
AU2010364538A1 (en) 2013-07-11
AU2010364538B2 (en) 2016-04-14
MX348337B (es) 2017-06-07
BR112013012811A2 (pt) 2016-09-13
EP2643344A1 (en) 2013-10-02
CA2818951A1 (en) 2012-05-31
IL226198A0 (en) 2013-07-31
JP6073239B2 (ja) 2017-02-01
CN103906760B (zh) 2017-02-22
SI2643344T1 (sl) 2017-07-31
HK1196379A1 (zh) 2014-12-12
JP2014501723A (ja) 2014-01-23
WO2012069089A1 (en) 2012-05-31
HUE033501T2 (en) 2017-12-28
KR101765364B1 (ko) 2017-08-08
BR112013012811B1 (pt) 2021-07-06
MX2013005820A (es) 2013-07-12
PL2643344T3 (pl) 2017-09-29
US20130302342A1 (en) 2013-11-14
CN103906760A (zh) 2014-07-02
ES2627960T3 (es) 2017-08-01
IL226198B (en) 2019-01-31
RU2573422C2 (ru) 2016-01-20
KR20130119955A (ko) 2013-11-01

Similar Documents

Publication Publication Date Title
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112013012811B8 (pt) Peptídeo derivado de lactoferrina humana, e processo para preparação de uma composição farmacêutica para liberação de uma substância ativa biológica em um organismo mamífero
BR112013026308A2 (pt) Compostos de benzeno substituídos
CR20140542A (es) Anticuerpos biespecíficos anti-vegf7anti-ang-2 y su utilización en el tratamiento de enfermedades vasculares oculares
BR112018000604A2 (pt) moléculas de anticorpo que ligam cd45
BR112015022566A2 (pt) composto e composição farmacêutica
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
BR112012027055A8 (pt) agente estabilizante para proteínas farmacêuticas.
CR20130264A (es) Compuestos pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por lp-pla2
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
BR112015011158A8 (pt) triazolopirazina, seu uso e preparação farmacêutica
DOP2012000246A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112014026952A8 (pt) derivados de aminopirimidina pirazol, seus usos, e composição
BR112017000313A2 (pt) sistema para o fornecimento de uma composição para tratamento bucal, composição para tratamento bucal, método para administrar uma composição para tratamento bucal
BR112014018421A8 (pt) Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
BR112018000632A2 (pt) moléculas de anticorpo que ligam a cd79
BR112012009432A2 (pt) anticorpo anti-hsv
BR112015028278A2 (pt) processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos
BR112015005653A2 (pt) Método de promover o desenvolvimento de oócitos maduros e de aumentar a polimerização de actina em tecido ovariano, e uso de um agente que perturba a sinalização na trajetória hippo, ou um agente que age a jusante da sinalização hippo perturbada
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/11/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25D Requested change of name of applicant approved

Owner name: ROEHM GMBH (DE)

B25G Requested change of headquarter approved

Owner name: ROEHM GMBH (DE)

B25A Requested transfer of rights approved

Owner name: EVONIK DEGUSSA GMBH (DE)

B25D Requested change of name of applicant approved

Owner name: EVONIK OPERATIONS GMBH (DE)